Verona Pharma (VRP) - Update on RPL554 Clinical Study
The RNS released this morning looks encouraging, see below:
--------------------------------- Start of RNS Summary ---------------------------------------------------------------------------------------------
29 Sep 2015 07:00:00
Verona Pharma PLC
Verona Pharma plc
("Verona Pharma" or the "Company")
Positive headline data from RPL554 clinical study in COPD patients
New suspension formulation is well tolerated; results signal marked improvement in lung function
RPL554 remains on track for entry into Phase IIb clinical trials in 2H 2016
29 September 2015, Cardiff ? Verona Pharma plc (AIM: VRP.L), the drug development company focused on first-in-class medicines to treat respiratory diseases, today announces encouraging positive headline data of the third and final part (part C) of a randomised, double blind, placebo controlled Single Ascending Dose (SAD) / Multiple Ascending Dose (MAD) clinical study in stable chronic obstructive pulmonary disease (COPD) patients. This study uses a new proprietary and commercially scalable nebulised suspension formulation of the Company?s lead pipeline drug, RPL554.1,2 The primary objective of this part of the study was to show the safety and tolerability of the new drug formulation in stable COPD patients with moderate severity of disease.3 Measurement of lung function using FEV14 was included. Evaluation of the full data set is ongoing and will be presented in an appropriate scientific, peer-reviewed forum at a later date.
Highlights: Part C of study in 32 stable COPD patients with moderate disease severity3
- Primary objective of study met: Drug formulation well tolerated at all dose levels; No serious adverse events reported
- Adverse event profile similar to that seen with placebo
- Absence of gastro-intestinal or cardiovascular adverse events
- RPL554 caused pronounced improvement in lung function
- Mean peak FEV1 increase ranged from 199ml to 257ml versus placebo
- Extent of bronchodilation exceeds that seen in earlier studies with original proof of concept formulation
- Data continue to support twice daily dosing regimen with RPL554
- Data consistent with that from earlier part A and B of study in healthy volunteers
- Evaluation of the full data set from this trial is ongoing
------------------------------------------- End of RNS Summary ----------------------------------------------------------------------------------
The Sharescope price graph is also very interesting...
 |
| Verona Pharma - SharePrice Graph (10 months) |
Summary
The news-flow has been positive for Verona Pharma, in relation to RPL554 and it could eventually cause this share to "take off". As ever, it's a matter of judgement as to whether to invest (and when)... take a look and let me know what you think.
Mick (29th September 2015)
